Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. NASDAQ:LIMN (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.As previously disclosed, on January 15, 2026 the Company received a notice from Nasda…